Haisco grants license to Sentivera; ViiV's HIV treatment OK'd for newborns

Haisco licenses inflammatory drug to Sentivera for $40M upfront, $36M stock, $1.46B milestones; FDA OKs ViiV's dolutegravir for newborns; Noetik hits GSK milestone.

Raccontata daendpoints.news